Valneva (DB:AYJ0) - Stock Price, News & Analysis

AYJ0 Stock Overview

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details

AYJ0 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 98.6% below our estimate of its fair value

Earnings are forecast to grow 4.63% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been diluted in the past year

Has less than 1 year of cash runway

Valneva SE Competitors

Formycon

XTRA:FYB

€827.2m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Biotest

XTRA:BIO3

€1.4b

Medigene

XTRA:MDG1

€22.6m

Price History & Performance

Summary of all time highs, changes and price drops for Valneva
Historical stock prices
Current Share Price	€3.92
52 Week High	€10.40
52 Week Low	€3.84
Beta	1.02
11 Month Change	-22.38%
3 Month Change	-39.22%
1 Year Change	-62.31%
33 Year Change	-92.74%
5 Year Change	n/a
Change since IPO	-83.80%

Recent updates

Shareholder Returns

	AYJ0	DE Biotechs	DE Market
7D	-8.8%	0.8%	-1.3%
1Y	-62.3%	-17.5%	7.4%

Return vs Industry: AYJ0 underperformed the German Biotechs industry which returned -17.5% over the past year.

Return vs Market: AYJ0 underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is AYJ0's price volatile compared to industry and market?
AYJ0 volatility
AYJ0 Average Weekly Movement	5.7%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: AYJ0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: AYJ0's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	700	Thomas Lingelbach	valneva.com

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

Valneva SE Fundamentals Summary

How do Valneva's earnings and revenue compare to its market cap?
AYJ0 fundamental statistics
Market cap	€332.86m
Earnings (TTM)	-€7.42m
Revenue (TTM)	€158.54m

2.1x

P/S Ratio

-44.9x

P/E Ratio

Is AYJ0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AYJ0 income statement (TTM)
Revenue	€158.54m
Cost of Revenue	€163.61m
Gross Profit	-€5.08m
Other Expenses	€2.34m
Earnings	-€7.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 20, 2025

Earnings per share (EPS)	-0.046
Gross Margin	-3.20%
Net Profit Margin	-4.68%
Debt/Equity Ratio	79.4%

How did AYJ0 perform over the long term?

See historical performance and comparison

AYJ0 Stock Overview

Rewards

Risk Analysis

Valneva SE Competitors

XTRA:FYB

€827.2m

XTRA:HPHA

€103.9m

XTRA:BIO3

€1.4b

XTRA:MDG1

€22.6m

Price History & Performance

Recent News & Updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva Announces Board Appointments

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COVID-19 Vaccine Candidate

Valneva SE Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Heterologous Booster Trial of Inactivated, Covid-19 Vaccine Candidate

Valneva SE, Annual General Meeting, Jun 23, 2022

Valneva Provides Regulatory Update on Its Inactivated Covid-19 Vaccine Candidate

Shareholder Returns

Price Volatility